Clinical Trials for Pancreas Cancer

A Phase 1/2, Open-label, Multicenter, Dose-escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants With Advanced Solid Tumors

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

HealthScout AI summary: This trial enrolls adults with advanced HRR-mutated solid tumors—including previously treated breast, ovarian, fallopian tube, primary peritoneal, castration-resistant prostate, or pancreatic cancers—who may have had limited prior PARP inhibitor exposure and CNS metastases if stable. Patients receive EIK1004 (IMP1707), a highly selective CNS-penetrant PARP1 inhibitor, as oral monotherapy.

ClinicalTrials.gov ID: NCT06907043

A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with locally advanced, unresectable, or metastatic HER2-expressing solid tumors (excluding breast, gastric, and colorectal), including biliary tract, bladder, cervical, endometrial, ovarian, pancreatic, and rare tumors, who have progressed after prior therapy or lack alternative options. All patients receive trastuzumab deruxtecan, a HER2-targeted antibody-drug conjugate delivering a topoisomerase I inhibitor to HER2-expressing tumor cells.

ClinicalTrials.gov ID: NCT04482309

Phase 1/2 Study of Neratinib and Divalproex Sodium (Valproate) in Advanced Solid Tumors, With an Expansion Cohort in Ras-Mutated Cancers

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Enrolling adults with advanced solid tumors—including RAS-mutated colorectal, pancreatic, other RAS-mutant tumors, EGFR-altered or RAS-mutant glioblastoma, and ocular melanoma (with GNAQ or GNA11 mutations)—this study tests oral neratinib (an irreversible pan-HER tyrosine kinase inhibitor) combined with divalproex sodium (a histone deacetylase inhibitor) in patients who have progressed on standard therapies.

ClinicalTrials.gov ID: NCT03919292

Phase 1 Study With Dose Expansion of the Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with unresectable, locally advanced, metastatic, or recurrent mesothelioma (epithelioid or biphasic with >80% epithelioid), or other solid tumors with high mesothelin expression (≥50% of tumor cells), who have progressed after standard therapies. Treatment involves lymphodepleting chemotherapy followed by a single infusion of autologous CAR T cells (TNhYP218) engineered to target a membrane-proximal epitope of mesothelin, using naive/stem cell memory T cells to potentially enhance efficacy.

ClinicalTrials.gov ID: NCT06885697

First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma after at least one prior systemic therapy undergo [68Ga]Ga DOTA-5G PET/CT selection, then receive [177Lu]Lu DOTA-ABM-5G radioligand therapy. The investigational theranostic pair targets DOTA-5G–avid lesions to confirm uptake for enrollment and deliver lutetium-177 beta radiation to tumors.

ClinicalTrials.gov ID: NCT04665947

Optimizing Ultrasound Enhanced Delivery of Therapeutics

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with newly diagnosed, locally advanced or metastatic pancreatic ductal adenocarcinoma (ECOG 0–2) eligible for standard chemotherapy (gemcitabine/nab-paclitaxel or FOLFIRINOX) are randomized to chemo alone versus chemo plus ultrasound-mediated sonoporation using perflubutane microbubbles (Sonazoid). Sonazoid microbubbles are an imaging contrast agent used investigationally here to transiently increase vascular/cellular permeability and enhance intratumoral drug delivery.

ClinicalTrials.gov ID: NCT04821284

A Phase 1b Study of Gemcitabine and Leflunomide in Patients With Unresectable Pancreatic Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with unresectable advanced pancreatic ductal adenocarcinoma (ECOG 0–1) planned for single-agent gemcitabine receive gemcitabine plus oral leflunomide, an immunomodulatory antiproliferative agent whose active metabolite inhibits dihydroorotate dehydrogenase (pyrimidine synthesis) and may inhibit tyrosine kinases. The study evaluates safety, DLTs, and preliminary efficacy of this combination, with key exclusions for recent systemic therapy, infection, and significant drug–drug interactions.

ClinicalTrials.gov ID: NCT06454383

Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following Induction With Sequential IV Gemcitabine Plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with ECOG 0–1, locally advanced unresectable pancreatic adenocarcinoma without metastases receive induction IV gemcitabine+nab-paclitaxel and SBRT, then are randomized to targeted intra-arterial gemcitabine via the RenovoCath dual-balloon catheter (arterial isolation to increase locoregional delivery) versus continuation of standard IV gemcitabine+nab-paclitaxel. Post-treatment, both arms may continue systemic therapy (gemcitabine/nab-paclitaxel or capecitabine) at investigator discretion until progression.

ClinicalTrials.gov ID: NCT03257033

Redefining The Use Of A FOLFIRINOX-Like Regimen In the Front Line In Older Patients With Metastatic Pancreatic Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Enrolling adults ≥65 with ECOG 0–2 metastatic pancreatic adenocarcinoma who are considered ineligible for standard FOLFIRINOX, including those with prior adjuvant therapy completed >6 months. Patients receive an alternating FOLFOX (oxaliplatin/5-FU/leucovorin) and FOLFIRI (irinotecan/5-FU/leucovorin) schedule every 28 days to deliver FOLFIRINOX components sequentially to improve tolerability.

ClinicalTrials.gov ID: NCT05360732

A Phase 1 Study of Olaparib in Combination With Durvalumab (MEDI4736) and Concurrent Radiation Therapy Following First-Line Chemotherapy in Locally Advanced Unresectable Pancreatic Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with unresectable, locally advanced pancreatic adenocarcinoma (ECOG 0–1) who completed ≥16 weeks of first-line chemotherapy without progression receive olaparib (PARP1/2 inhibitor) plus durvalumab (anti–PD-L1) with hypofractionated external beam radiation starting cycle 2. Excludes prior PD-1/PD-L1, PARP inhibitors, upper abdominal RT, and germline BRCA1/2 mutation.

ClinicalTrials.gov ID: NCT05411094